Eurppse : To evaluate the presence of Neuron Specific Enolase (NSE) in subretinal fluid (SRF? as a uotential marker for retinal damaee and to correlate these b&Vets 'tith r&al detachment (RD) pzmmwem kS.E is a reliablemarkerofneuronallysisintbecerebro-~fluidinbraindamage. Levels of NSE in the aqueous humour are also elevated in retiwblastoma NSEhaskdetectedinalllayenofnmmal humanretinaexcepth4uller cells and retinal pigment epithelimn. Methods : SRF and blood samples were collected during RD before cryc4hempy (CT) in 3 cases (Group l), a&r CT in 18 cases (Group 2). be&Fmzd after CT in 2 cases (Croup 3). NSE was measured with a mtoassay (sensitivity In&l). We had no &zence values for subretinat fluid Normal range is c 15ng/ml. in aqueous humor (collected in 10patientspriortocatamctsmgery). ~:MeanlevelsofNSEinSRFingroup2(1264f881n%ml)-significantly higher (p< 0.01) than those in group 1 (157 f 114 n&l Eurppse: Cerebral toxoplasmosis is the nwst common opportunistic mfection of the central nervous system in AIDS-patients. The treatment of ocular toxoplasmosis with c&entional drug r$mes sulphadiacin'or clindamycin plus pyrimethamine can occasionally produce swerc side effects and adverse reactions. But maintenance therapy must be continued for life time because of the high recurrence rates. Atavaquone is a new hydroxynaphthoquione which is tolerated excellently by the pattients The drug is very effective against tachycoits of toxoplasma gcmdii and its cysts as well. -A 29-yeardld female with HIV-infection developed an allergic rash after being treated with a course of pyrimethamine and clindamycin (Sobellin) for unilateral, unifocal ocular toxoplasmosis for 14 days. Therapy with atovaquone (4 x 750 mg/dl was administered. Within I4 days the infiltrate disappeared resulting a chorioretinal scar. j3smk
The oral treatment with atovaquone (4 x 750 mg/d) was not accompanied with allergic complications. During maintenance therapy with atovaquone (3 x 7% mg/dl no rearrency occurred during a period of 9 month. The vitreous haze stadily decreased and the chorioretinal scar was pigmented. Conclusion: In this patient atovaquone proved to be an effective and well tolerated drug for the treatment of ocular toxoplasmosis. It might believe that atcwaquone is a valid alternate to standard drugs such as renmws with pyrimethakine, clindamycin or sulfonamides wh;h otherwisp are often complicated by toxic side effects and allergic reactions. Future clinical investigations will have to evaluate whether atovaquone will be a real alternate in longterm treatment of ocular toxoplasmosis.
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